Supernus Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 delivered strong revenue growth, driven by ONAPGO's rebound, robust Qelbree and ZURZUVAE performance, and improved operating results. Guidance for 2026 was reiterated, with a solid cash position and no debt supporting future growth.
-
Record 2025 revenue and a revamped portfolio with four growth drivers set the stage for 2026, with balanced contributions expected from Qelbree, Gocovri, Zurzuvae, and ONAPGO. Continued investment in marketing and R&D supports strong revenue growth and a robust pipeline, with key data readouts anticipated in 2027.
-
The company has resolved ONAPGO supply issues and resumed new patient starts, with strong demand and a $45–$70 million revenue outlook. Qelbree and ZURZUVAE continue to grow, supported by increased investment and education, while pipeline assets advance toward 2027 data.
Fiscal Year 2025
-
Record 2025 revenues of $719 million were driven by strong growth in Qelbree, GOCOVRI, Zurzuvae, and ONAPGO, with successful integration of Sage Therapeutics and resolution of ONAPGO supply constraints. 2026 guidance projects continued double-digit revenue growth and robust product demand.
-
Integration of the Sage acquisition is ahead of plan, with $200M in annualized synergies targeted. ZURZUVAE and Qelbree are both experiencing strong demand-driven growth, while APOKYN supply constraints are being addressed through alternative manufacturing. Pipeline assets SPN-820 and SPN-817 are advancing in clinical development.
-
Supply constraints for ONAPGO are being addressed through current and alternative suppliers, with FDA involvement and long-term plans for a second supplier. Demand remains strong, especially among advanced Parkinson’s patients, and ZURZUVAE is expanding in the postpartum depression market, primarily through OB-GYNs.
-
Revenue guidance is $685–$705 million, driven by four CNS products, with Qelbree and Onapgo showing strong growth. Onapgo faces supply constraints, while Zurzuvae is expanding in postpartum depression. Business development and pipeline expansion remain key priorities.
-
Q3 2025 saw strong revenue growth from key products, with ONAPGO, Qelbree, GOCOVRI, and ZURZUVAE driving 78% of total revenues. Guidance for 2025 was raised, though ONAPGO supply constraints are limiting new patient starts. Cash remains strong with no debt.
-
Transitioning to a new growth phase, the company leverages a diversified CNS portfolio, highlighted by Qelbree and Zurzuvae, and maintains profitability. Strategic M&A and partnerships, robust product performance, and a focused R&D pipeline position the business for continued expansion.
-
A CNS-focused company is accelerating growth with new launches in ADHD, Parkinson’s, and postpartum depression. Qelbree is gaining traction as a non-stimulant ADHD option, ONAPGO’s early launch is promising, and ZURZUVAE is expanding awareness and screening for postpartum depression.
-
Q2 2025 saw robust growth from Qelbree, GOCOVRI, and ONAPGO, now 73% of net sales, while legacy products declined. Revenue guidance for 2025 was raised following the Sage acquisition, with ZURZUVAE showing strong early momentum. Cash position remains strong post-acquisition.
-
The acquisition brings a first-in-class oral treatment for postpartum depression, diversifies the portfolio, and is expected to be significantly accretive by 2026. Up to $200 million in annual synergies are anticipated, with strong commercial momentum and minimal payer barriers supporting long-term growth.
-
A CNS-focused biopharma is driving growth with Qelbree for ADHD and ONAPGO for Parkinson's, both showing strong early performance and multi-hundred million dollar potential. Pipeline assets in depression and epilepsy target 2027 data, while active business development seeks new commercial opportunities.
-
Core products Qelbree and GOCOVRI drove double-digit revenue growth in Q1 2025, offsetting declines in legacy products. ONAPGO launched with strong initial uptake, and the company maintains robust liquidity and reiterates 2025 guidance.
-
Strong 2023 results and a robust 2025 outlook are driven by Qelbree’s rapid growth and the upcoming launch of a new Parkinson’s infusion device. Qelbree is expanding in both pediatric and adult ADHD markets, while the Parkinson’s portfolio is set to grow with a fourth product launch.
-
2024 saw strong revenue growth driven by Qelbree, offsetting legacy product declines and supporting robust cash flows. Key pipeline updates include ongoing SPN-820 and SPN-817 studies, with strategic decisions expected soon. APO-go launches in Q2, and Qelbree continues to expand in both pediatric and adult ADHD markets.
Fiscal Year 2024
-
Core product growth drove strong 2024 results, with Qelbree prescriptions up 25% and net sales up 72% year-over-year. 2025 guidance anticipates $600M–$630M in revenue, continued investment in pipeline, and minimal SPN-830 sales contribution.
-
SPN-830 is on track for a potential 2025 launch, with regulatory hurdles addressed and strong commercial infrastructure in place. Qelbree continues robust growth in both pediatric and adult segments, while the company seeks late-stage assets to fill future pipeline gaps and advances multiple clinical programs.
-
A CNS-focused company is navigating a transition as legacy products lose exclusivity, with Qelbree driving growth and new launches planned for 2025. Promising pipeline assets in epilepsy and depression are advancing, and a Parkinson’s infusion device is expected to launch pending FDA approval.
-
Q3 2024 saw strong revenue and earnings growth, led by Qelbree and GOCOVRI, with robust pipeline progress and a raised full-year outlook. Cash position strengthened to $403.2 million, and guidance for 2024 was increased across key metrics.
-
SPN-820 showed rapid and substantial reduction in depressive symptoms and suicidal ideation in a Phase 2a open-label study, with effects sustained for 10 days and a favorable safety profile. Most participants reached remission, and only mild or moderate adverse events were observed.
-
SPN-820 and SPN-817 are progressing through key clinical milestones, with pivotal data expected by year-end and early next year. Qelbree is gaining momentum in the ADHD market, supported by strong prescription growth and improved gross-to-net dynamics. The product is positioned for significant long-term sales potential.
-
A CNS-focused biopharma is driving growth through internal R&D, targeted M&A, and a robust pipeline. Qelbree is expanding in ADHD, while legacy products face generic erosion. Key pipeline assets, including a novel antidepressant and Parkinson’s pump, are expected to deliver major catalysts in 2024–2025.
-
Q2 2024 saw robust revenue and prescription growth for key products, especially Qelbree, which achieved record sales and expanded its adult market share. Guidance for 2024 was raised, with strong cash generation and ongoing pipeline progress supporting future growth.
-
Revenue guidance remains steady as growth shifts to Qelbree and GOCOVRI, with Qelbree showing strong script momentum and a multi-hundred-million-dollar opportunity. Pipeline assets SPN-817 and SPN-820 are advancing, with key data readouts expected in the next 12 months.